Novo at a Crossroads: Will Its Strategic Plan Deliver?

Novo, formerly Novo Nordisk, unveiled a strategic growth plan aiming to launch more than five blockbuster drugs by 2030, expanding beyond obesity and diabetes into blood, endocrine, liver, and cardiovascular diseases while also growing direct-to-consumer telehealth channels. The company is pursuing multiple Phase III programs, preparing for regulatory decisions like the FDA review of CagriSema, and expanding through acquisitions such as Kallyope's obesity drug programs.

This Wire brief sits within Fusion42's coverage of Biotech.